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Vitiligo and other hypopigmentation disorders in children 
and adolescents
Sonja Prćić1, Verica Đuran2, Dragan Katanić1
Th  e loss of pigment, either partial (hypopigmentation) or complete 
(depigmentation), can have a major psychological impact on patients. 
Hypopigmentation disorders, congenital and acquired, are very nu-
merous, and many of them are rarely seen. Th  is paper provides an 
overview of the most common hypopigmentation disorders in chil-
dren and adolescents, stressing the importance of vitiligo and autoim-
mune disorders in patients. Vitiligo is an acquired disease, possibly of 
autoimmune nature, sometimes with a clear hereditary component, 
which is characterized by progressive, clearly defi  ned, milky white 
spots on the skin and/or mucous membranes. In about 50% of patients 
vitiligo occurs before 20 years of age. Th   e clinical picture of vitiligo in 
children and adolescents is similar to adults, but there are some dif-
ferences in the epidemiology, their associations with other endocrine 
and/or autoimmune diseases and treatment of vitiligo in children 
compared to adult patients.
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Introduction
Pigmentation disorders can be congenital or acquired. 
Congenital disorders of pigmentation, oft  en result from 
mutations of many genes that govern the processes of de-
velopment of melanoblasts, their migratory movements 
towards the periphery, and their diff  erentiation into ma-
ture melanocytes that produce pigment. Th  e acquired 
pigmentation disorders are mainly due to qualitative or 
quantitative defects of melanocytes (e.g. vitiligo) in the 
skin and mucous membrane (1, 2).
Th  e loss of pigment, either partial (hypopigmenta-
tion) or complete (depigmentation), can have a major 
psychological impact on patients. In many religious writ-
ings, depigmentation is described as a sign of dangerous, 
communicable diseases (3). In ancient times, vitiligo was 
equated with leprosy, in which hypopigmentation also 
occurs, and these patients were varying degrees of social 
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outcasts (1, 2, 4). Although it is now known 
that most hypopigmented changes in the 
skin are not contagious and dangerous, loss 
of pigment causes psychological problems 
for a large number of patients (5). Many skin 
diseases are accompanied by hypopigmenta-
tion or depigmentation. Vitiligo, pityriasis 
alba and pityriasis versicolor and varietas 
alba are seen in everyday clinical practice, 
and these diseases will be discussed (6).
Vitiligo
Vitiligo is an acquired disease, possibly au-
toimmune by nature, sometimes with a clear 
hereditary component, which is character-
ized by progressive, clearly circumscribed,   
milky white spots on the skin and/ or mu-
cous membranes. Th  e name vitiligo comes 
from the Latin vitium (anomaly) or vitelius 
(white patches on calf’s fur) (1, 2, 3).
Epidemiology
Vitiligo occurs among people of all races 
and climates. It is believed that 1-2% of the 
world’s population is aff  ected. It can occur 
in all age groups, but in half the patients it 
occurs before 20 years of age (1, 2, 3, 4, 7). 
Some authors suggest that 25% of patients 
fi  rst develop the symptoms before the age of 
eight, and 50% of patients prior to 10 years 
(7, 8, 9).
Th   e epidemiology of vitiligo in children 
is similar to adults, but there are certain 
characteristics of children’s vitiligo. Un-
like adults, where the frequency of vitiligo 
in both sexes is about the same, vitiligo in 
children is more common in girls (10). A 
family history of associated endocrine and / 
or autoimmune disease is more common in 
children with vitiligo than in adult patients. 
Vitiligo is present in the family history of 
12% to 35% of aff  ected children, as opposed 
to about 8% of adult patients (7, 10, 11, 12).
Th   e etiology and pathogenesis of 
vitiligo
Th  e etiology and pathogenesis of vitiligo 
is not fully explained. It is known that ge-
netic factors play a role in the development 
of vitiligo: a positive family history in up to 
30% of patients, described cases of vitiligo in 
twins, and the fact that vitiligo occurs with 
diseases that have a clear genetic basis, such 
as diabetes mellitus, suggests that role (3, 4, 
13). Recent research suggests two possible 
modes of inheritance of vitiligo, which are 
associated with the age at which vitiligo ap-
peared (14). In patients with early onset of   
vitiligo (before age 30), vitiligo is caused by 
the dominant mode of inheritance with in-
complete penetration. However, in patients 
with late onset (aft  er age 30), predisposition 
to vitiligo is the result of a recessive geno-
type and the infl  uence of the external envi-
ronment (15, 16). An earlier start of vitiligo 
(up to 7 years) was found in children with 
vitiligo and a positive family history of viti-
ligo (17). Th   ere is clear evidence of the as-
sociation of certain MHC haplotypes with 
a positive family history of vitiligo, onset 
timing, severity of disease and ethnic origin 
(15, 16). As a possible theory for the etiology 
of vitiligo the following are cited: the auto-
immune, oxidative stress theory (theory of 
self-destruction of melanocytes) and the 
neurogenic theory (1, 2, 3, 4).
Th  e autoimmune theory is supported 
by experimental evidence and clinical as-
sociation with other autoimmune diseases: 
pernicious anemia, Addison’s disease, type 1 
diabetes mellitus (T1DM), juvenile rheuma-
toid arthritis, alopecia areata and especially 
Hashimoto’s thyroiditis (1, 3, 18, 19, 20, 21). 
Vitiligo is relatively common in of autoim-
mune polyglandular insuffi   ciency syndrome 
(APS), especially in type I (APS-I), where 
25% of patients have vitiligo (22). Patients 
with vitiligo oft  en have organ-specifi  c se-
rum autoantibodies, especially antithyroid 176
(antithyroglobulin and antibodies against 
thyreoperoxidase) and antiparietal auto-
antibodies. Some research suggests that an 
increased incidence of autoimmune thy-
roiditis in patients with vitiligo is genetically 
determined. Th   e locus on chromosome 1 - 
AIS1 (engl. autoimmunity susceptibility), re-
sponsible for the tendency to autoimmune 
responses, particularly for vitiligo, in the 
presence of other genes (e.g. the main histo-
compatibility complex localized on the short 
arm of chromosome 6), combined with ex-
posure to external or internal factors, may 
mediate in the development of Hashimoto’s 
thyroiditis in patients whose AIS1 is sus-
ceptible (23, 24). It is known that genes on 
chromosome 17p13 contribute to the de-
velopment of certain autoimmune diseases, 
which include generalized vitiligo, autoim-
mune thyroiditis, T1DM, rheumatoid ar-
thritis, psoriasis, pernicious anemia, sys-
temic lupus erythematosus, and Addison’s 
disease. Recent studies describe the NALP1 
protein as a gene that regulates the intact-
ness of the immune system. Changes in the   
DNA sequence in the NALP1 domain, are 
associated with an increased risk of general-
ized vitiligo and/or other joint autoimmune 
diseases, such as autoimmune thyroiditis 
(25). It is believed that autoimmune mecha-
nisms play a key role in the pathogenesis of 
non- segmental vitiligo (4).
Th   e melanocytes of active vitiligo reveal 
an increase in oxidants and antioxidant en-
zyme defi  cit, with resultant oxidative dam-
age to melanocytes (3, 26, 27). Th  e emer-
gence of segmental vitiligo can be best ex-
plained by the neurogenic theory according 
to which the nerve endings release the neu-
rochemical mediators that inhibit melano-
genesis or have toxic eff  ects on melanocytes, 
destroying them. Microscopic examination 
and ultrastructural investigations in people 
with segmental vitiligo showed damage to 
axons and disrupted neuropeptide balance 
in vitiligo lesions (27, 28). As possible pro-
voking factors for the occurrence of vitiligo 
the following are cited: stress, sun burns, re-
current skin injuries. It is believed that dif-
ferent mechanisms may cause the same phe-
notype: vitiligo is a heterogeneous disease in 
terms of etiology (2, 4).
Clinical characteristics of vitiligo
Th   e main change in vitiligo is depigmented 
macula, usually round or oval-shaped, milky 
white color, with a diameter of several milli-
meters to several centimeters (1, 2, 3, 4). Th  e 
skin surface in vitiligo is smooth. Atypical 
maculae (artifi  cial) appear at the site of in-
jury, lacerations, friction and burns and are 
the result of Köebner’s phenomenon (1). Vit-
Table 1 Characteristics of non-segmental and segmental vitiligo
Characteristics  Non-segmental vitiligo Segmental vitiligo
Prevalence (%)  72-95 5-8
Distribution pattern Symmetrical, not limited to the 
dermatome
Unilateral, limited to the dermatome
Onset Any age Young age
Course Variable, often new lesions occurring 
during life (progressive course)
Initial rapid progression, then the activity of 
lesions limited to the period up to 2 years
Köebner’s phenomenon Often present Rarely present
Association with autoimmune 
diseases
Frequent Extremely  rare
Etiology Probably autoimmune likely neurochemical
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iligo can occur anywhere on the skin. Pre-
dilection sites are around the natural open-
ings - the eyes, mouth, nipples, navel and 
genitals. In the majority of patients vitiligo 
lesions fi  rst appear on skin exposed to the 
sun. In vitiligo patients polyosis  commonly 
occurs (“white lock of hair”) and halo nevus 
(Sutton nevus) (3).
Vitiligo can be divided into the non-seg-
mental and segmental forms of the disease 
(1, 2, 4, 9). In segmental vitiligo depigment-
ed plaques are limited to a dermatome. Th  e 
characteristics of these two types of vitiligo 
are given in Table 1. In clinical practice the 
generally accepted classifi  cation of vitiligo is 
by Kovacs (3). According to this classifi  ca-
tion, vitiligo is divided into focal, segmental, 
generalized, acrofacial and universal types, 
which diff  er not only morphologically but 
also in their natural course, response to 
treatment and prognosis (1, 2, 3).
Th   e association of vitiligo with other 
endocrine and / or autoimmune 
diseases
Adult patients with vitiligo, especially with 
the generalized form of the disease, are at 
increased risk of developing a number of 
endocrine and / or autoimmune diseases, 
including thyroid disease, T1DM, perni-
cious anemia, Addison’s disease, rheumatoid 
arthritis and alopecia areata. Vitiligo can 
occur before, concurrently or aft  er the oc-
currence of one or more endocrine and / or 
autoimmune diseases (1, 3). Epidemiological 
studies, carried out on a large number of chil-
dren with vitiligo, showed no increased risk 
of contracting one of these endocrine and / 
or autoimmune diseases (10, 29, 30, 31, 32).
Patients with vitiligo most commonly 
suff  er from thyroid disease (30-40%), pre-
cisely  Hashimoto’s thyroiditis, then hyper-
thyroidism, hypothyroidism and Graves-
Basedow’s disease (1, 33, 34, 35). Unlike 
adults, children and adolescents with viti-
ligo demonstrate increased frequency of 
exclusively Hashimoto’s thyroiditis. Consid-
ering the fact that vitiligo usually precedes 
autoimmune thyroiditis, a possible early di-
agnosis of the latter is possible. It is therefore 
recommended that children and adolescents 
with non-segmental vitiligo undergo annual 
screening for antibodies against thyreoper-
oxidase (TPO-Ab), antithyroglobulin an-
tibodies (Tg-Ab) and thyroid-stimulating 
hormone (TSH) (36, 37, 38).
Th  erapy
Treatment of vitiligo should be initiated with 
a consultant dermatologist, aft  er presenting 
therapeutic possibilities and their eff  ective-
ness to the patient. Th   e choice of therapeutic 
options depends primarily on the age and 
type of vitiligo patients. In all cases it is nec-
essary to use measures to protect against so-
lar radiation and use photoprotective meth-
ods (1, 2, 39, 40).
– Phototherapy.  Th  ere are two basic 
forms of generalized vitiligo photo-
therapy: PUVA (Psoralen + UVA) pho-
tochemotherapy using photosensitive 
drug (8-metoxypsoralen) in combina-
tion with UVA radiation (320-400 nm 
wavelength) and UVB rays of narrow 
range of wavelengths of 311 nm (Nar-
row -band UVB). Targeted laser photo-
therapy is recommended for focal viti-
ligo (2, 41, 42).
–  Local corticosteroid therapy: treat-
ment for at least 3 to 4 months (watch 
for side eff  ects of corticosteroids!) (7).
–  Other forms of local therapy (mela-
genin, calcineurin-inhibitors / pimecro-
limus, tacrolimus /, calcipotriol, pseu-
docatalase) (43, 44, 45)
– Depigmentation (monobenzyl hydro-
quinone ether and 4-methoxy-phenol 
as a cream) with extensive and general-
ized vitiligo only in adults and adoles-
cents (2).
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– Surgical treatment (epidermal graft  ing 
obtained by suction, autologous skin 
graft    method, mini-transplantations) 
is the method of choice for segmental 
vitiligo in adults and adolescents (46).
– Cosmetic camoufl  age methods (47).
Th  e  diff  erential diagnosis of vitiligo
Th  e diagnosis of vitiligo is set on the basis 
of history and the characteristic clinical pic-
ture, additional laboratory analysis are rarely 
needed, skin biopsy even rarer. In children 
there may be diff  erential diagnostic diffi   cul-
ties in relation to other diseases that are ac-
companied by hypopigmentation, such as 
pityriasis alba, pityriasis versicolor varietas 
alba, post-infl  ammatory  hypopigmenta-
tion, piebaldism, morfea, leprosy, tuberous 
sclerosis, naevus depigmentosus and lichen 
sclerosus et atrophicus (4, 6). A special dif-
fi  culty for the recognition of vitiligo arises 
in fair-skinned people, where it is harder 
to spot hypopigmentation or depigmenta-
tion. A Wood’s lamp (emitting UV rays with   
wavelengths of 320-400 nm, with a maxi-
mum of 365 nm), makes it possible to spot 
the diff  erences between the complete loss of 
pigment in vitiligo and various other dis-
eases accompanied by hypopigmentation. 
Knowing the type of inheritance, the char-
acteristic clinical patterns and symptoms of 
these diseases is necessary to set an accurate 
diagnosis of vitiligo (4, 6, 11).
Pityriasis alba
Pityriasis alba (PA) is a common, benign, lo-
calized form of hypopigmentation, which is 
more common in children than in adults. In 
children under 12 years of age, prevalence is 
between 1.9% and 5.25% (2, 48).
Th  e etiology and pathogenesis of PA is 
not clarifi  ed. Th   ere is a perception that the 
disease is more common in dark-skinned 
people. PA is considered a minor form of 
atopic dermatitis. Recent studies have indi-
cated the frequent occurrence of PA in in-
dividuals who sunbathe without using pho-
toprotection, and the onset of PA as a result 
of frequent sunbathing. In these patients the 
low levels of serum copper was detected, and 
it is known that copper plays an important 
role in the synthesis of tyrosinase, which 
may explain the hypopigmentation (6, 48).
Th   e clinical pattern shows unclearly bor-
dered hypopigmented maculae and pityria-
sis-like  desquamation on their surface. Th  e 
disease begins with an erythematous plaque 
with elevated edges and  desquamation oc-
curs aft  er several weeks. Hypopigmentation 
can last from 6 months to 7 years. Th  e  course 
is prolonged in patients with atopic dermati-
tis. PA is an asymptomatic disease, although 
there may be mild itching. Th   e changes are 
mainly localized on the head, neck and up-
per limbs. Th  e most common localizations 
are the head, the forehead and cheekbones, 
and it rarely occurs in periorbital and peri-
oral regions, unlike vitiligo. Th   ere is a gen-
eralized form of atypical PA, which is more 
oft  en seen in adults, and the changes are lo-
calized to the thorax (1, 2, 6, 48).
Th   e therapy involves emollients and cor-
ticosteroid creams of low and moderate po-
tency, which have limited eff  ectiveness. Th  e 
use photoprotective creams is recommend-
ed. Aft  er a few months or years the condi-
tion spontaneously withdraws. In the exten-
sive form in adolescents and adults PUVA 
therapy is applied (48).
Pityriasis versicolor alba varietas
Th  e cause of the disease is Pityrosporum 
ovale (synonyms: Pityrosporum orbiculare, 
Malassezia furfur,  Malassezia ovalis), part 
of the normal fl  ora of the skin, which under 
certain circumstances is transformed from 
saprophytic yeasts into the mycelal phase 
and leads to skin diseases. Th   e disease is not 
contagious and occurs in predisposed peo-
Acta Medica Academica 2011;40:174-181179
ple, mostly in areas with a humid and warm 
climate (6, 49).
Th  e clinical picture is presented with 
café-au-lait or yellowish-brown (versicolor) 
maculae which are circular, oval or irregular 
in shape, with unclear edges, up to 1 cm in 
diameter, with pityriasis-like desquamation 
at the surface (apparent aft  er mild curretage 
of the macula) and with a tendency to con-
fl  uence in plaques. Th   e maculae have charac-
teristic distribution sites, with localization on 
the chest, back and upper half of the upper 
arm, and in children they occur on the head 
and neck. In immunodefi  cient  conditions, 
the skin changes have atypical distribution 
(inverse) and the face, creases and some parts 
of the limbs are aff  ected. Th   e maculae become 
hypopigmented aft  er sunbathing (Pityriasis 
versicolor alba varietas) but hypopigmenta-
tion is reversible. An asymptomatic infection 
is the most common, itching is rarely present. 
If left   untreated, the course becomes chronic 
and could last for years (49).
Diagnosis is made based on the clinical 
features and the use of a Wood’s lamp, when   
the yellowish-orange fl  uorescence of the af-
fected skin is noticed. Native mycological 
examination with KOH reveals the char-
acteristic appearance of hyphae and spores   
(“spaghetti and meatballs”) (6, 48, 49).
Local therapy is the method of choice, 
and imidazole compounds are advised 
(1% Econazole, Ketoconazole 2%) and ci-
clopiroxolamine in the form of a solution, 
spray or cream 1-2 times a day for 2-4 
weeks. Selenium sulfi  de 2.5% shampoo and 
zinc pyrithione shampoo used once a day 
(foam should be left   on the skin 10 minutes), 
for two weeks. Residual hypopigmentation 
lasts a few months aft  er healing, which pa-
tients should be warned about. Th  e  disease 
may recur, since Pityrosporum ovale belongs 
to the normal saprophytic fl  ora of the skin. 
Systemic therapy is not recommended be-
cause Pityrosporum ovale is a normal inhab-
itant of the skin and cannot be completely 
removed. For prevention of the disease, a 
soap is recommended containing Zn and Se 
sulfi  de for washing, with mild friction with 
keratolytics during the summer months as 
well as the use of a sulfi  de shampoo with Se 
and Zn pyrithione, once a week (6, 48, 49). 
Piebaldism
Piebaldism is a rare (incidence is 2.5/100000) 
autosomal dominant disorder caused by 
the irregular development of melanocytes, 
which is manifested by the focal absence of 
melanocytes in the aff  ected skin and hair fol-
licles. Th   e clinical picture is characterized by 
polyosis and multiple, symmetrical, leuko-
dermic maculae, typically distributed on the 
sides of the trunk, the anterior abdominal 
wall and above and below the elbows and 
knees. Polyosis on the forehead is present in 
80-90% of patients. Unlike vitiligo, piebald-
ism does not appear on the hands, feet and 
periorifi  cial areas. Hyperpigmented macu-
lae within amelanotic depigmented areas are 
typical (1, 2, 4).
In patients with piebaldism mutations of 
C-kit proto-oncogene are found, which en-
codes the transmembrane receptor and ty-
rosine kinase activity, causing the omission 
of migration and diff  erentiation of melano-
blasts from the neural tube during embry-
onic development, in the aff  ected skin areas. 
Phenotypic characteristics are fully formed 
at birth and permanent, and usually do not 
spread aft  erwards (1, 2). Th  erapy is symp-
tomatic and includes photoprotection and 
allows the use of cosmetic camoufl  age (1, 2).
Tuberous sclerosis
Tuberous sclerosis is an autosomal domi-
nant determined, multisystemic neurocuta-
neous syndrome, characterized by the for-
mation of multiple hamartomas usually lo-
calized in the skin, brain, heart, kidney, liver 
and lungs. In 2/3 of the patients the disease 
is the result of sporadic mutations. Th  e  char-
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acteristic triad consists of deafness, mental 
retardation and cutaneous angiofi  bromas, 
and is seen in only 29% of patients. Early 
diagnosis is important. At birth or during 
the fi  rst months of life in 97.2% of patients 
hypopigmented maculae are observed (3 
or more), beige-whitish or yellow-whitish 
in color. Th   ey represent a major diagnostic 
sign.  Ash-leaf spots or spear-like and po-
lygonal maculae, sized 0.5 to 2 cm, localized 
mainly on the trunk or upper legs are char-
acteristic. Less commonly confetti macula 
or macula of dermatome schedule are seen. 
Size can vary from 4 mm to 12 cm. Later, 
chagrin plate, facial angiofi  bromas, periun-
gual fi  bromas and plaque on the forehead 
could emerge. Systemic manifestations of 
tuberous sclerosis fall within the scope of 
pediatrics (1, 2, 4, 50).
Confl  ict of interest: Th  e authors declare that they 
have no confl  ict of interest. Th   is study was not spon-
sored by any external organization.
Authors’ contributions: Conception and design: SP; 
Acquisition, analysis, interpretation of data: SP; Draft  -
ing the article: SP and DK; Revising it critically for im-
portant intellectual content: VD and DK.
References
1.  Ortonne JP, Bahdoran P, Fitzpatrick TB, Mosher 
DB, Hori Y. Hypomelanoses and hypermelanoses. 
In: Fitzpatrick TB, Freedberg IM, Eisen AZ, Wolff   
K, Austen KF, Goldsmith LA, eds. Fitzpatrick’s 
Dermatology in general medicine. 6th ed, New 
York: Mc Graw-Hill Proff  esional; 2003. p. 839-47.
2.  Pavlović MD. Poremećaji pigmentacije. 
U: Karadaglić Đ. Dermatologija. Beograd: 
Vojnoizdavački zavod; 2000. p. 871-902.
3. Kovacs SO. Vitiligo. J Am Acad Dermatol. 
1998;38:647-66. 
4.  Huggins RH, Schwartz RA, Janniger CK. Vitiligo. 
Acta Dermatoven APA. 2005;4(14): 137-45.
5.  Schmid-Ott G, Kunsebeck HW, Jecht E, Shim-
shoni R, Lazaroff   I, Schallmayer S, et al. Stigmati-
zation experience, coping and sense of coherence 
in vitiligo patients. J Eur Acad Dermatol Venereol. 
2007;46:990-5.
6.  Lio PA. Little white spots: an approach to hy-
popigmented macules. Arch Dis Child Ed Pract. 
2008;93:98-102.
7.  Halder RM. Childhood vitiligo. Clin Dermatol. 
1997;15:899-906.
8.  Hurwitz S. Disorders of pigmentation. In: Hurwitz 
S. Clinical pediatric dermatology. Philadelphia: W. 
B. Saunders Company; 1993. p.458-60. 
9.  Janniger CK. Childhood vitiligo. Cutis. 1993;51:25-8.
10. Handa S, Dogra S. Epidemiology of childhood 
vitiligo: a study of 625 patients from north India. 
Pediatr Dermatol. 2003;20:207-10. 
11. Huggins RH, Schwartz RA, Janniger CK. Child-
hood vitiligo. Cutis Cutaneous Medicine For Th  e 
Practitioner. 2007;79(4):277-80. 
12. Prcic S, Djuran V, Katanic D. Vitiligo in children 
and adolescents: a literature review.  Serb J Der-
matol Venereol. 2010;2(3):95-104.
13. Deng GY, Muir A, Maclaren NK, She JX. Associa-
tion of LMP2 and LMP7 gnes within MHC with in-
sulin- dependent diabetes mellitus: population and 
family studies. Am J Hum Gen. 1995;56:528-34.   
14. Arcos-Burgos M, Parodi E, Salgar M, Bedoya E, 
Builes J, Jaramillo D, et al. Vitiligo: complex seg-
regation and linkage disequilibrium analyses with 
respect to microsatelite loci spanning the HLA. 
Hum Genet. 2002;110:334-42.
15. Zamani M, Spaepen M, Sghar SS, Huang C, 
Westerhof W, Nieuweboer-Krobotova L, et al. 
Linkage and association of HLA class II genes 
with vitiligo in a Dutch population. Br J Dermatol. 
2001;145:90-4.
16.  Ando I, Chi HI, Nakagawa H, Otsuka F. Diff  erence 
in clinical features and HLA antigenes between fa-
milial and non-familial vitiligo of non-segmental 
type. Br J Dermatol. 1993;129:408-10.
17. Pajvani U, Ahmad N, Wiley A, Levy RM, Kundu 
R, Mancini AJ, et al. Th  e relationship between 
family medical history and childhood vitiligo. J 
Am Acad Dermatol. 2006;55(2):238-44.
18. Prahalad S, Kingsbury DJ, Griffi   n  TA,  Cooper 
BL, Glass DN, Maksimowych WP, et al. Polymor-
phism in the MHC- encoded LMP7 gene: associa-
tion with JRA without functional signifi  cance for 
immunoproteasome assembly. J Rheumatol. 2001; 
28:2320-5.   
19.  Njoo MD, Westerhof W. Vitiligo. Pathogenesis and 
treatment. Am J Clin Dermatol. 2001;2(3):167-81.
20.  Taieb A. Intrinsic and extrinsic pathomechanismus 
in vitiligo. Pigment Cell Res. 2000;13 Suppl:841-7.
21. Kemp EH, Waterman EA, Weetman AP. Au-
toimmune aspects of vitiligo. Autoimmunity. 
2001;34:653.
22.  Alkhateeb A, Fain RP, Th   ody A, Bennett CD, Spritz 
RA. Epidemiology of vitiligo and associated auto-
immune diseases in Causian probands and their 
families. Pigment Cell Res. 2003;16 Suppl:208-14.181
23. Fain PR, Gowan K, La berge GS, Alkhateeb A, 
Stetler GL, Talbert J, et al. A genomewide screen 
for generalized vitiligo: confi   rmation of AIS1 
on chromosome 1p31 and evidence for ad-
ditional susceptibility loci. Am J Hum Genet. 
2003;72:1560-4.
24. Alkhateeb A, Stetler GL, Old W, Talbert J, Uni-
horn C, Taylor M, et al. Mapping of an autoimmu-
nity susceptibility locus (AIS1) to chromosome 
1p31.3-p.32.2. Hum Mol Genet.2002;11:661-7.
25. Jin Y, Mailloux CM, Gowan K, Riccardi SL, La-
Berge G, Bennett DC, et al. NALP 1 in vitiligo- as-
sociated multiple autoimmune disease. N Engl J 
Med. 2007;356:1216-25.
26. Passi S, De Luca S, Stancato A, Maggro F, Gran-
dinetti M. Epidermal oxidative stress in vitiligo. 
Pigment Cell Res. 1998;11:81-5.
27. Gauthier Y, Cario Andre M, Taieb A. A critical 
appraisal of vitiligo etiologic theories. Is melano-
cyte loss a melanocytorrhagy? Pigment Cell Res. 
2003;16:322-32.
28. Liu PY, Johansson O, Loutz W, Bondesson L. 
Th  e occurrence of cutaneous nerve endings and 
neuropeptides in vitiligo vulgaris: a case-control 
study. Arch Dermatol Res. 1996;288:670-5.
29. Cho S, Kang HC, Hahm JH. Characteristics of vit-
iligo in Korean children. Pediatr Dermatol. 2000; 
17:189-93.
30. Zhi H, Jiang-Bo L, Sui- Sui M, Sen Yang, Xue-
Jun Z. Profi  le of childhood  vitiligo in China: an 
analysis of 541 patients. Pediatr Dermatol. 2006; 
23(2):114-6.
31. Al-Mutairi N, Sharma AK, Al-Sheltawy M, Nour-
Eldin O. Childhood vitiligo: a prospective hospi-
tal-based study. Aust J Dermatol. 2005; 46:150-3.
32. Prcic S, Duran V, Mikov A, Mikov I. Vitiligo in 
children. Pediatr Dermatol. 2007;24(6):666. 
33. Hegedus L, Heidenheim M, Gevril M, Hjalgrim 
H, Hoiert-Madsen M. High frequency of thyroid 
dysfunction in patients with vitiligo. Acta Derm 
Venereol. 1994;74:120-3.
34. Zetting G, Tanew A, Fisher G, Mayr W, Dudczak 
R, Weissel M. Autoimmune diseases in vitiligo: do 
antinuclear antibodies decrease thyroid volume? 
Clin Exp Immunol. 2003;131:347-54.
35. Schallreuter KU, Lemke R, Brandt O, Schwartz 
R, Westhofen M, Montz R, Berger J. Vitiligo and 
other diseases: coexistence or true association? 
Hamburg study on 321 patients. Dermatology. 
1994;l88:269-75.
36. Iacovelli P, Sinagra J, Paro Vidolin A, Marenda S, 
Capitanio B, Leone G, et al. Relevance of thyroid-
itis and of other autoimmune diseases in children 
with vitiligo. Dermatology. 2005;210:26-30.
37. Kakourou T, Kanaka-Gantenbein C, Papadopou-
lou A, Kaloumenou E, Chrousous G. Increased 
prevalence of chronic autoimmune (Hashimoto’s) 
thyroiditis in children and adolescents with viti-
ligo. J Am Acad Dermatol. 2005;220-3.
38. Prćić S. ¨Vitiligo i poremećaji funkcije štitaste 
žlezde kod dece i adolescenata¨. Doktorska  teza. 
Novi Sad, Srbija: Medicinski fakultet Univerziteta 
u Novom Sadu: 2009.
39. Parsad D, Pandhi R, Dogra S, Kumar B. Clinical 
study of repigmentation patterns  with diff  er-
ent treatments modalities and their correlation 
with speed and stability of repigmentation in 
352 vitiliginous patches. J Am Acad Dermatol. 
2004;50:63-7.
40. Grimes PE. Whites patches and bruised souls: ad-
vances in pathogenesis and treatment of vitiligo. J 
Am Acad Dermatol. 2004;51:85-7.
41. Njoo MD, Bos JD, Westerhof W. Treatment of 
generalised vitiligo in children with narrow-band 
(TL-01) UVB radiation therapy. J Am Acad Der-
matol. 2000;245-3.
42. Hadi SM. Spencer JM. Lebwohl M. Th  e use of 
308-nm excimer laser for the treatment of vitiligo. 
Dermatol Surg. 2004;140:677-83.
43.  Xu AE, Wei XD. Topical melagenine for repigmen-
tation in twenty-two child patients with vitiligo on 
the scalp. Chinese Med J. 2004;117:199-201.
44. Silverberg NB, Lin P, Travis L, Farley-Li J, Man-
cini AJ, Wagner AM, et al.. Tacrolimus ointment 
promotes repigmentation of vitiligo in chil-
dren: a review of 57 cases. J Am Acad Dermatol. 
2004;51:760-6.
45.  Gargoom AM, Duweb GA, Elzorghany AH, Beng-
hazil M, Bugrein OO. Calcipotriol in the treat-
ment of childhood vitiligo. Int J Clin Pharmacol 
Res. 2004;24:11-4.
46. Gupta S, Kumar B. Epidermal graft  ing for vitiligo 
in adolescents. Pediatr Dermatol. 2002;19:159-62.
47. Tedeshi A, Dall Oglio F, Micali G, Schwartz RA, 
Janniger CK. Corrective camoufl  age in pediatric 
dermatology. Cutis. 2007;79:110-2.
48. Richie L, Janniger C. Pityriasis alba. Cutis Cutane-
ous Medicine For Th   e Practitioner. 2005;76:21-4.
49. Nelson MM, Martin AG, Hefernan MP. Fungal 
diseases with cutaneous involment. In: Freedberg 
IM, Eisen AZ, Wolff   K, Austen KF, Goldsmith LA, 
eds. Fitzpatrick ‘s Dermatology in general medi-
cine. 6th ed, New York: Mc Graw-Hill Proff  esion-
al; 2003. p. 1989-2034.
50. Schwartz R, Fernandez G, Kotylska K, Jozwiak S. 
Tuberous sclerosis complex: advances in diagno-
sis, genetics, and management. J Am Acad Der-
matol. 2007:189-202.
Sonja Prćić, et. al.: Vitiligo and other hypopigmentation disorders